Nanozyme-Powered Immunotherapy via Concurrent Niche Disruption and Checkpoint Blockade for Acute Myeloid Leukemia.
Acute myeloid leukemia (AML) relapse and drug resistance remain major causes of mortality in hematologic malignancies, driven in part by CXCR4/CXCL12-mediated homing and retention of leukemic cells within the bone marrow niche, as well as immune evasion mechanisms that enable their persistent survival. Here, we report...